New Allergan Aesthetics Research Highlights Rising Aesthetic Needs Among GLP-1 Weight Loss Patients

Allergan Aesthetics, a division of AbbVie, has released new data highlighting how the growing use of medical weight loss (MWL) therapies is reshaping patient behavior and treatment demand in aesthetic medicine. The findings indicate that patients undergoing significant weight loss are increasingly seeking aesthetic consultations, particularly to address facial changes such as volume loss and skin quality concerns.

As rapid weight loss can accelerate visible changes in facial structure, many patients are visiting aesthetic clinics for the first time to explore treatment options. Experts suggest that early consultations and proactive treatment planning are essential to help patients understand available solutions and achieve balanced, natural-looking results. In many cases, hyaluronic acid dermal fillers are being used to restore facial volume and maintain a natural appearance following weight loss.

"Allergan Aesthetics is committed to equipping our customers with data-driven insights, education, and consultation tools to help guide patients safely and effectively through these changes," said Glen Curran, Senior Vice President at Allergan Aesthetics. "We're seeing this new patient population enter aesthetics with different concerns, different goals, and a strong desire for individualized, long-term treatment and care, particularly when it comes to restoring facial balance and volume."

The data also shows a rising consumer interest in professional aesthetic procedures. Approximately 40% of patients receiving medical weight-loss treatments are considering aesthetic procedures in physician offices or medical spas. At the same time, aesthetic practices are increasingly becoming a key entry point for these therapies, with about 60% of patients taking GLP-1 medications receiving them from healthcare providers who also offer aesthetic treatments, an increase from roughly half just a year earlier.

Research conducted by Allergan Aesthetics indicates that physicians are observing noticeable shifts in patient concerns and treatment preferences. Among individuals using GLP-1–based weight-loss therapies, 61% experience midface volume loss, 50% report skin laxity, and 35% notice wrinkles or facial folds following weight reduction. These changes are driving demand for targeted aesthetic solutions that help restore facial balance.

"As a dermatologist, I've seen firsthand how medical weight loss can significantly impact the face," said Dr. Joely Kaufman, a board-certified dermatologist in Miami, FL. "This data reflects what we're seeing in practice: patients who are excited about their weight loss success are looking for personalised, medically appropriate solutions that restore balance and confidence."

Healthcare professionals report that hyaluronic acid fillers are one of the most commonly recommended non-surgical treatments for patients experiencing these effects, with 81% of clinicians identifying them as a leading option after GLP-1-related weight loss. Additionally, about one-third of physicians say the rise of GLP-1 usage has increased dermal filler procedures in their practices. These insights build on research presented at the American Society for Dermatologic Surgery Annual Meeting in 2025 and later published in the Aesthetic Surgery Journal Open Forum, reflecting the growing intersection between medical weight loss and aesthetic medicine.